Ntrust-1: A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CARNK) Cell Therapy, in Subjects with Immune-Mediated Diseases

Project: Research

Status	Active
Effective start/end date	11/24/25 → 11/23/26

Project Details